Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423820
Status:
RECRUITING
Last Update Posted:
2024-05-22
First Post:
2024-05-16
Brief Title:
Preoperative Ondansetron Lozenge for Prevention of Postoperative Nausea and Vomiting in Pediatrics Undergoing Squint Surgeries
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
Preoperative Ondansetron Lozenge for Prevention of Postoperative Nausea and Vomiting in Pediatrics Undergoing Squint Surgeries A Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the role of ondansetron lozenge on prevention of postoperative nausea and vomiting PONV in pediatrics undergoing squint surgeries
Detailed Description:
Post-operative nausea and vomiting PONV are two of the most common and distressing complications related to surgery and anesthesia
In several studies PONV occurred in 13 to 42 of pediatric surgical patients while severe cases are less common occurring in 1-3 of patients Volatile anesthetics are the main cause in the early post-operative period 0-2 h with dose-response relationship In the delayed post-operative period 2-24 h the main predictors are childhood PONV in the early period and the use of postoperative opioids
Ondansetron is generally considered to be the first-line antiemetic for patients because of its favorable side effect profile Ondansetron reduces the activity of the vagus nerve which deactivates the vomiting center in the medulla oblongata and also blocks serotonin receptors in the chemoreceptor trigger zone Ondansetron is an effective drug in the prevention and treatment of PONV by having low side effects
In several studies PONV occurred in 13 to 42 of pediatric surgical patients while severe cases are less common occurring in 1-3 of patients Volatile anesthetics are the main cause in the early post-operative period 0-2 h with dose-response relationship In the delayed post-operative period 2-24 h the main predictors are childhood PONV in the early period and the use of postoperative opioids
Ondansetron is generally considered to be the first-line antiemetic for patients because of its favorable side effect profile Ondansetron reduces the activity of the vagus nerve which deactivates the vomiting center in the medulla oblongata and also blocks serotonin receptors in the chemoreceptor trigger zone Ondansetron is an effective drug in the prevention and treatment of PONV by having low side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None